Ertugliflozin offers some kidney protection

Prof. David Cherney

Home > Endocrinology > EASD 2020

EASD 56th Annual Meeting European Association for the Study of Diabetes 21-25 September 2020

EASD 2020 Highlights Podcast

Presented By

Dr Rachel Giles, Medicom

EASD Round-Up Articles

Ertugliflozin offers some kidney protection

Presented By

Prof. David Cherney, University of Toronto, Canada

DAPA-CKD trial shows extensive benefits of dapagliflozin

Presented By

Prof. Hiddo Heerspink, University of Groningen, the Netherlands

Empagliflozin significantly reduces CV and renal risk

Presented By

Dr Milton Packer, Baylor University Medical Center, Dallas, USA

Poor prognosis for T2D patients on loop diuretics in addition to SGLT2 inhibitor

Presented By

Prof. Pierpaolo Pellicori, University of Glasgow, United Kingdom

Once daily oral treatment with glucokinase activator TTP399 reduced HbA1c in patients with type 1 diabetes

High risk of vascular dementia in patients with T2D

Presented By

Dr Carlos Celis-Morales, University of Glasgow, Scotland

HbA1c reduction with GLP-1RA leads to lower risk of CV events in cardiovascular outcome trials

Presented By

Dr Mart Roosimaa , University of Tartu, Estonia

Diabetes still goes unnoticed, resulting in delayed diagnosis

Presented By

Dr Katie Young, University of Exeter Medical School, United Kingdom

Shared pathways for COVID-19 and diabetes?

Patients with RA have higher risk of developing diabetes

Presented By

Dr Zixing Tian, University of Manchester, United Kingdom

Once-weekly insulin is a promising treatment option

Presented By

Dr Julio Rosenstock, University of Texas Southwestern, USA

Non-invasive monitoring by measuring glycated albumin in tears

Presented By

Dr Masakazu Aihara, University of Tokyo, Japan

More exercise means less risk of all-cause mortality amongst T2D patients.

Presented By

Dr Yun-Ju Lai , Taichung Veterans General Hospital, Taiwan

Intermittent fasting: consuming fewer calories but in a different way.

Presented By

Prof. Krista Varady, University of Illinois, Chicago, USA

Medical Conferences

EASD 2020

Table of Contents

Featured articles

EASD 2020 Highlights Podcast

EASD Round-Up Articles

Ertugliflozin offers some kidney protection

DAPA-CKD trial shows extensive benefits of dapagliflozin

Empagliflozin significantly reduces CV and renal risk

Poor prognosis for T2D patients on loop diuretics in addition to SGLT2 inhibitor

Once daily oral treatment with glucokinase activator TTP399 reduced HbA1c in patients with type 1 diabetes

High risk of vascular dementia in patients with T2D

HbA1c reduction with GLP-1RA leads to lower risk of CV events in cardiovascular outcome trials

Diabetes still goes unnoticed, resulting in delayed diagnosis

Shared pathways for COVID-19 and diabetes?

Patients with RA have higher risk of developing diabetes

Once-weekly insulin is a promising treatment option

Non-invasive monitoring by measuring glycated albumin in tears

More exercise means less risk of all-cause mortality amongst T2D patients.

Intermittent fasting: consuming fewer calories but in a different way.

Timing of mealtime insulin can affect quality of life